➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
AstraZeneca
Merck
Express Scripts
McKesson

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METROGEL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Metrogel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00249782 A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea. Completed Allergan Phase 2 2005-11-01 The purpose of this study is to evaluate the safety and effectiveness of ACZONE™ gel compared to placebo (inactive substance), MetroGel® and a combination of ACZONE™ gel and MetroGel® for the treatment of rosacea. ACZONE™ gel, 5% is a topical (applied to the skin) medication that is approved by the United States Food and Drug Administration (FDA) for the treatment of acne vulgaris in people 12 years and older. The use of ACZONE™ for the treatment of rosacea is investigational. An investigational use is one that is not approved by the FDA. Subjects will apply the study treatment for 12 weeks. Efficacy assessments will be performed at baseline and Weeks 2, 4, 8, and 12. Laboratory assessments will be conducted at baseline and Week, 2, 4 and 12.
NCT00436527 Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application Completed Galderma Laboratories, L.P. Phase 4 2006-08-01 This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.
NCT00635622 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed University of California, San Francisco Phase 2 2008-04-01 This is a phase IIa clinical trial in women with bacterial vaginosis. This study will determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy (metronidazole) is effective in colonizing the vagina with the lactobacillus bacteria found in normal vaginal flora.
NCT00635622 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed Osel, Inc. Phase 2 2008-04-01 This is a phase IIa clinical trial in women with bacterial vaginosis. This study will determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy (metronidazole) is effective in colonizing the vagina with the lactobacillus bacteria found in normal vaginal flora.
NCT00668655 An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1% Completed Galderma Laboratories, L.P. N/A 2008-02-01 The purpose of this study is to determine the cosmetic appearance of metronidazole gel (MetroGel®) 1% with commonly marketed facial foundations.
NCT01020396 Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis Completed Teva Pharmaceuticals USA Phase 1/Phase 2 2002-01-01 The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical equivalence in the treatment of bacterial vaginosis.
NCT01020877 Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects Completed Teva Pharmaceuticals USA Phase 1 2001-11-01 The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Metrogel

Condition Name

Condition Name for Metrogel
Intervention Trials
Bacterial Vaginosis 4
Rosacea 4
Skin Manifestations 2
Bacterial Vaginosis (BV) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Metrogel
Intervention Trials
Vaginosis, Bacterial 5
Vaginal Diseases 5
Rosacea 5
Skin Manifestations 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Metrogel

Trials by Country

Trials by Country for Metrogel
Location Trials
United States 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Metrogel
Location Trials
Pennsylvania 6
California 6
North Carolina 4
Florida 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Metrogel

Clinical Trial Phase

Clinical Trial Phase for Metrogel
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Metrogel
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 1
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Metrogel

Sponsor Name

Sponsor Name for Metrogel
Sponsor Trials
Galderma Laboratories, L.P. 5
Teva Pharmaceuticals USA 2
Osel, Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Metrogel
Sponsor Trials
Industry 13
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Harvard Business School
Colorcon
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.